| 總結: | Introduction: About 25% of patients with diabetes mellitus have painful diabetic peripheral neuropathy (PDPN). Chronic hyperglycemia causes neuronal death and nerve regeneration inhibition, causing diabetic neuropathy. It may severely impair touch, vibration, and lower-limb proprioception. Materials and Methods: This prospective observational study included patients with PDPN and uncontrolled with pregabalin for at least 3 months. Patients receiving a fixed-dose combination of nortriptyline–pregabalin (10 mg/75 mg) and duloxetine–pregabalin (20 mg/75 mg) were included in the study (50 patients in each group). The patients were followed-up at intervals of 4, 12, and 24 weeks to assess the clinical improvement and adverse effect profile. Results: The mean age was 52.09 ± 12.34, and duration of diabetes was 6.03 ± 3.11 years. No significant differences were noted in the visual analogue scale (VAS) score at baseline. A significant difference was noted in VAS scores at 4 weeks, 12 weeks, and 24 weeks both within and between the groups. The decline in the VAS score was significantly higher in the pregabalin and duloxetine group. Adverse events were reported in 39% of participants, and they were mild in severity. Conclusion: Both FDCs provided therapeutic benefit in pain relief. Overall, duloxetine–pregabalin had better pain relief than nortriptyline–pregabalin.
|
|---|
